Drug Trial Radar · NCT06900192
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Jun 2028
Study completion Dec 2032
Sponsor
- Lead sponsor
- Orca Biosystems, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).
Conditions
- Primary Progressive Multiple Sclerosis
- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
Interventions
Orca-QBiological
Allogeneic (donor) stem cell graft
myeloablative regimenDrug
Myeloablative regimen of busulfan, fludarabine, and thiotepa.
TacrolimusDrug
Graft-versus-host disease (GVHD) prevention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe acute graft-versus-host-disease-free survivalTime frame: Up to 6 months after infusion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.